EGFR L838V

CI-VAR-00002430Explore in graph →NP_005219.2:p.Leu838ValNM_005228.4:c.2512C>GClinVar 208822 CIViC 1018 rs864621996

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
EGFR L838V	Erlotinib + GefitinibSubstitutes	Predictive	D	Supports Resistance	2	accepted	EID4280 In an in vitro study, a Ba/F3 cell line expressing EGFR L838V demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sen… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
208822	Uncertain significance	no assertion criteria provided	0	Lung carcinoma	germline	1	Jun 27, 2013	clinvar